Meningoencephalitis following ipilimumab administration in metastatic melanoma

American Journal of the Medical Sciences

Volumn 350, Issue 6, 2015, Pages 512-513

  Stein, Matthew K ^a   Summers, Bryant B ^a   Wong, Christine A ^a   Box, Hilary L ^a   Cleveland, Kerry O ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; CEFTRIAXONE; ETHAMBUTOL; GLUCOSE; IPILIMUMAB; ISONIAZID; LINEZOLID; MEROPENEM; METHYLPREDNISOLONE SODIUM SUCCINATE; PYRAZINAMIDE; RIFAMPICIN; VANCOMYCIN; MONOCLONAL ANTIBODY;

ABNORMAL RESPIRATORY SOUND; ADULT; AUDITORY HALLUCINATION; BRAIN BIOPSY; BRAIN DISEASE; CASE REPORT; CATARACT EXTRACTION; CEREBROSPINAL FLUID; DETERIORATION; DIAPHORESIS; DURA MATER; ELECTROENCEPHALOGRAPHY; EYE MELANOMA; FEVER; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; LAMINECTOMY; LASER SURGERY; LETTER; LEUKOCYTE; LIMB WEAKNESS; LUMBAR PUNCTURE; MALAISE; MALE; MEDICAL HISTORY; MENINGOENCEPHALITIS; MENTAL HEALTH; METASTATIC MELANOMA; MICROSCOPY; MIDDLE AGED; MOUTH MUCOSA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; RESPIRATORY TRACT DISEASE; TACHYCARDIA; TACHYPNEA; UPPER RESPIRATORY TRACT; VOMITING; EYE TUMOR; IMMUNOLOGY; LIVER TUMOR; MELANOMA; MENINGITIS, ASEPTIC; PATHOLOGY; SECONDARY;

ANTIBODIES, MONOCLONAL; EYE NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MENINGITIS, ASEPTIC; MENINGOENCEPHALITIS; MIDDLE AGED;

EID: 84952863785     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000584     Document Type: Article

References (8)

1. United States Food and Drug Administration (FDA). FDA Approved Drug Products. 2011. Available at: http://www. Accessdata. fda. gov/ drugsatfda-docs/nda/2011/125377Orig1s000SumR. pdf. Accessed March 18, 2015.
2. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013;8: e53745.
3. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30.
4. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
5. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-97.
6. German M, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis revisited. JAMA Intern Med 2014;174:1511-2.
7. Yervoy (R) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2014.
8. Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29. Abstract no: 8583.